Autopsy report · NCT02365415

Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

“Unable to enroll appropriate patients”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Boston Children's Hospital

Sponsor type

University, hospital or other

Conditions

Peripheral Pulmonary Stenosis; In-stent Stenosis

Interventions

Sirolimus

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
  “Unable to enroll patients” (96% match in meaning)
• Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation
  “Difficulty enrolling patients” (90% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (88% match in meaning)
• The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision
  “Unable to enroll more patients” (87% match in meaning)
• Outcome After Avascular Necrosis of the Femoral Head in Young Patients
  “difficulty enrolling patients, no patient recruited” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.